UPDATE: Connect Biopharma's Interim Topline Data from Phase 2 Study Shows Rademikibart Reduced Treatment Failure Rate At 28 Days By 66% (Though This Endpoint Did Not Reach Statistical Significance) And Improved Lung Function Vs. Placebo